Diagnosis of Prostate Cancer Using Anti-Psma Aptamer A10-3.2-Oriented Lipid Nanobubbles

International Journal of Nanomedicine - New Zealand
doi 10.2147/ijn.s112951
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2016English

Alpha-Pet for Prostate Cancer: Preclinical Investigation Using 149Tb-Psma-617

Scientific Reports
Multidisciplinary
2019English

Full Preclinical Validation of the 123i-Labeled Anti-Psma Antibody Fragment ScFvD2B for Prostate Cancer Imaging

Oncotarget
Oncology
2016English

225Ac-Psma-617 for PSMA-Targeted -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2016English

Immunohistochemical Validation of PSMA-expression Measured by 68 Ga-Psma PET/CT in Primary Prostate Cancer

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2017English

PSMA PET Ligands in Prostate Cancer: A Game‐changer?

Trends in Urology & Men's Health
2019English

Terbium-161 for PSMA-targeted Radionuclide Therapy of Prostate Cancer

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2019English

Modifying Cellular Properties Using Artificial Aptamer-Lipid Receptors

Scientific Reports
Multidisciplinary
2013English

Radioimmunotherapy (RIT) Dose-Escalation Studies in Prostate Cancer Using Anti-Psma Antibody 177Lu-J591: RIT Alone and RIT in Combination With Docetaxel

2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy